Despite a congressional inquiry finding fault with the FDA’s controversial approval of aducanumab (Aduhelm), the FDA continues to approve Alzheimer’s drugs that demonstrate little efficacy and high risk of deadly brain bleeding. According to a new BMJ investigation, financial conflicts of interest may help explain why. “A new...